Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

semaglutide use led to lower insulin requirements and increased weight loss. It showed greater benefits in participants with a higher body mass index, as they lost more weight and achieved greater ...